CAMBRIDGE, Mass. and ROSTOCK, Germany and HAMBURG, Germany and BERLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809), a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches, today announced that the two companies have expanded their existing drug discovery partnership related to Gaucher disease – a genetic lysosomal storage disorder caused by mutations in the glucocerebrosidase gene. The parties intend to develop a treatment for Gaucher patients.
Prof. Arndt Rolfs, CEO of CENTOGENE, said, “Our collaboration with Evotec further underlines CENTOGENE’s commitment to driving biomarker discoveries and accelerating orphan drug development by leveraging our global expertise in rare hereditary diseases. In particular, we are able to draw on over 20 years of knowledge and research of Gaucher disease. By continuing our work alongside Evotec, we will accelerate transformational medical solutions in the rare disease field.”Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “The partnership with CENTOGENE supports and complements our patient-centric drug discovery approach in Gaucher disease. We highly value CENTOGENE’s biomarker expertise and real-world data-based global proprietary rare disease platform, which fits perfectly to our iPSC-based drug discovery platform. The combination should help identify disease-modifying treatments for this underserved patient population.”Dr. Philip Lambert, Chief Scientific Officer at CENTOGENE, added, “The potential to further the understanding of rare diseases connected to mutations in the GBA gene is extremely important to patients and their families around the world, and we hope that today’s collaboration agreement will help lead to transformational personalized treatments for these patients.”Under the terms of the expanded agreement, CENTOGENE and Evotec will work together to research, discover, and develop medical solutions for rare diseases related to the protein target glucocerebrosidase (“GBA”), a well-known gene linked to Gaucher disease. The collaboration brings together Evotec’s leading induced pluripotent stem cell (“iPSC”) platform and broad drug discovery and development capabilities with CENTOGENE’s global proprietary rare disease platform, including insights as well as iPSC lines. Ultimately, the aim is to address the needs of this orphan drug indication. The collaboration builds on the partnership Evotec and CENTOGENE entered in 2018 with the goal to discover and develop novel small molecules in rare hereditary metabolic diseases.About Evotec SEEvotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,300 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women’s health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 3.0 billion weighted data points from over 530,000 patients representing over 120 different countries as of March 31, 2020.CENTOGENE
Ben Legg Corporate Communications Evotec Gabriele Hansen SVP Global Communications & Marketing
+49.(0)40.560 81-255 FTI Consulting Bridie Lawlor +1.917.929.5684
Bay Street News
